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Abstract
Endothelium dysfunction is one of the hallmarks of sepsis. Looney
and Mattay, in the previous issue of Critical Care, highlight the role
of activated protein C (APC) as a protective endothelial drug in
septic situations. Nevertheless, the results of in vivo studies are
less explicit and it remains uncertain whether these properties are
relevant in human septic shock. Before considering recombinant
APC (rAPC) as a therapeutic drug for the endothelium, we have to
demonstrate its efficiency to protect or to reduce endothelium
injury when infused a long time after the septic challenge.
Nevertheless, if rAPC is efficient when infused in the early phase of
septic challenge, we thus need to treat our patients earlier. At the
least, genetically engineered variants have been designed with
greater anti-apoptotic activity and reduced anticoagulant activity
relative to wild-type APC. Further studies are needed to demon-
strate the usefulness of these variants in septic shock therapy.
The use of recombinant activated protein C (rAPC) is one of
the hottest topics in septic shock therapy. The pivotal phase
3 placebo-controlled Protein C Worldwide Evaluation in
Severe Sepsis (PROWESS) clinical trial demonstrated a
19.4% relative risk reduction in 28-day mortality (6.1%
absolute risk reduction) with an increased risk (3.5% versus
2.0%) of serious bleeding events compared with placebo.
Two recent and important articles have highlighted the role of
APC as a protective endothelial drug [1] and as a cyto-
protective drug [2]. Beneficial effects of rAPC in the
PROWESS study were thought to be related to a reduction
in coagulation and, to a lesser extent, to a reduction in inflam-
matory response to sepsis [3]. Post-PROWESS investiga-
tions have been associated with a myriad of cellular or animal
studies demonstrating that rAPC, through reactions mediated
by endothelial protein C receptor and the effector receptor,
protease activated receptor-1, acts directly on cells to exert
multiple cytoprotective effects including: down regulation of
pro-inflammatory gene expression [4]; anti-inflammatory
activities [5]; anti-apoptotic activity [6]; and protection of
endothelial barrier function [1,2].
Endothelium dysfunction is one of the hallmarks of sepsis [7].
Sepsis, per se, may induce phenotypic modulations of the
endothelium through direct or indirect interaction of the
endothelial layer with components of the bacterial wall,
inducing a myriad of host-derived factors from endothelial
cells. Phenotypic modifications include changes in pro-
coagulant and proadhesive properties, increased endothelial
permeability, endothelial cell apoptosis and changes in
vasomotor properties; the last of these is crucial since
vasoplegia is directly related to septic shock mortality. Recent
animal and human data have suggested that rAPC may
improve both vascular and myocardial dysfunction and
vascular reactivity to catecholamine during endotoxin and/or
septic challenge [8,9].
From bench to bedside
Experimental evidence supports a role of APC in maintaining
the integrity of the endothelium through both direct and
indirect mechanisms. Nevertheless, the results of in vivo
studies are less explicit. In a retrospective study of septic
shock in humans, Monnet and colleagues [9] demonstrated
that APC infusion was associated with a decrease in the
amount of delivered norepinephrine. Wiel and colleagues
[10] demonstrated in a rabbit model of endotoxin induced
shock that APC decreased aorta endothelial injury. By
contrast, in a lung model of endotoxin induced inflammation,
Robriquet and colleagues [11] demonstrated a trend to an
increased vascular permeability using high doses of human
APC. This last result was in sharp contrast with the results
obtained by Nick and colleagues [12] in a human model of
pulmonary endotoxin administration. APC appears to improve
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mortality in septic shock with a high APACHE 2 score and is
potentially detrimental in severe sepsis. In rats, APC markedly
decreased tumour necrosis factor concentrations whereas
they remained unchanged in either human septic shock or
endotoxemia. The question arises, therefore, as to whether it
is truly possible to reconcile all these discrepancies? More-
over, can these stirring laboratory data be translated into
clinical practice?
Limitations of experimental studies:
endothelium protection versus endothelium
therapy
Clearly, in cellular and animal models, rAPC has been given
either as a pre-treatment or concurrent with septic challenge.
This mode of administration favours the anti-inflammatory
effects of rAPC, which are particularly efficient in murine
models in protecting the endothelium from cytokine-mediated
apoptosis or upregulation of endothelial adhesion molecules.
Thus, studies using post-injury treatment are needed in models
that mimic septic shock, such as experimental pneumonia or
peritonitis treated by antibiotics and volume resuscitation, and
where the effects of rAPC would be investigated 16 to
24 hours after septic challenge. If we can demonstrate the
efficiency of rAPC to protect or to reduce endothelium injury in
these conditions, we can ultimately postulate that rAPC is also
a therapeutic drug for the endothelium.
The earlier the better
If rAPC is efficient when infused in the early phase of septic
challenge, we thus need to treat our patients earlier. At least
two studies suggest that treatment with rAPC within 24 hours
may carry a larger survival advantage for patients with severe
sepsis, compared with those treated more than 24 hours
after organ dysfunction [13]. Interventions directed at specific
endpoints, when initiated early in the ‘golden hours’ of a
patient’s condition, seem to be promising [14]. The beneficial
effects of earlier administration of rAPC to appropriate
patients may fit into this paradigm.
The future
Extensive in vivo and in vitro studies have focused on the
cytoprotective effects of APC and most authors agree that its
anticoagulant and cytoprotective effects are mediated by
distinct APC structural features. Positively charged residues
in surface loops in the APC protease domain have been
identified as participating in the anticoagulant activity but not
in cellular effects. Hence, variants have been designed with
greater anti-apoptotic activity and reduced anticoagulant
activity relative to wild-type APC [2]. Whether these
genetically engineered variants actually provide superior
pharmacological properties remains to be elucidated in vivo.
Such investigations may allow the design of therapeutic APC
variants with decreased anticoagulant activity to reduce the
risk of bleeding on the one hand, but also with normal
cytoprotective properties in order to retain full beneficial
effects on sepsis outcome.
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